Halozyme Therapeutics Inc (HALO)
43.14
-0.72
(-1.63%)
USD |
NASDAQ |
May 10, 16:00
42.00
-1.14
(-2.65%)
After-Hours: 20:00
Halozyme Therapeutics Gross Profit (Quarterly): 167.55M for March 31, 2024
Gross Profit (Quarterly) Chart
Historical Gross Profit (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 167.55M |
December 31, 2023 | 177.74M |
September 30, 2023 | 161.21M |
June 30, 2023 | 170.97M |
March 31, 2023 | 126.97M |
December 31, 2022 | 139.38M |
September 30, 2022 | 161.66M |
June 30, 2022 | 118.42M |
March 31, 2022 | 101.36M |
December 31, 2021 | 80.42M |
September 30, 2021 | 97.24M |
June 30, 2021 | 113.44M |
March 31, 2021 | 70.80M |
December 31, 2020 | 95.43M |
September 30, 2020 | 59.75M |
June 30, 2020 | 49.48M |
March 31, 2020 | 19.57M |
December 31, 2019 | 36.98M |
September 30, 2019 | 23.90M |
June 30, 2019 | 37.27M |
March 31, 2019 | 52.30M |
December 31, 2018 | 54.61M |
September 30, 2018 | 24.93M |
June 30, 2018 | 34.37M |
March 31, 2018 | 27.82M |
Date | Value |
---|---|
December 31, 2017 | 182.08M |
September 30, 2017 | 55.40M |
June 30, 2017 | 25.96M |
March 31, 2017 | 22.02M |
December 31, 2016 | 31.00M |
September 30, 2016 | 22.72M |
June 30, 2016 | 25.03M |
March 31, 2016 | 34.74M |
December 31, 2015 | 43.80M |
September 30, 2015 | 14.60M |
June 30, 2015 | 35.24M |
March 31, 2015 | 12.17M |
December 31, 2014 | 24.23M |
September 30, 2014 | 9.465M |
June 30, 2014 | 12.46M |
March 31, 2014 | 6.446M |
December 31, 2013 | 8.958M |
September 30, 2013 | 15.33M |
June 30, 2013 | 13.17M |
March 31, 2013 | 11.10M |
December 31, 2012 | 21.14M |
September 30, 2012 | 5.108M |
June 30, 2012 | 7.614M |
March 31, 2012 | 7.369M |
December 31, 2011 | 2.355M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (Quarterly) Range, Past 5 Years
19.57M
Minimum
Mar 2020
177.74M
Maximum
Dec 2023
100.48M
Average
99.30M
Median
Gross Profit (Quarterly) Benchmarks
Novavax Inc | 98.42M |
Globus Medical Inc | 365.18M |
Denali Therapeutics Inc | -- |
AIM ImmunoTech Inc | 0.053M |
Protalix BioTherapeutics Inc | 1.63M |